PolyPeptide Group AG (CH:PPGN)
:PPGN
Want to see CH:PPGN full AI Analyst Report?
Top Page
PolyPeptide Group AG
(PPGN)
Select Model
Select Model
Rating:54Neutral
Price Target:
CHF37.00
▲(24.16% Upside)
Action:ReiteratedDate:04/14/26
The score is driven primarily by mixed financial performance: solid revenue growth and improving operating cash flow are offset by ongoing net losses and volatile free cash flow, with leverage trending higher. Technicals are supportive due to a strong uptrend, but momentum is stretched. Valuation is a headwind because the company is loss-making (negative P/E) and no dividend yield is available.
Positive Factors
Consistent Revenue Growth
Steady revenue growth (including +6.2% in 2025) indicates expanding commercial traction in peptide CDMO services. Durable top-line expansion supports scale economics, underpins capacity investments, and raises the probability of sustained margin recovery if commercial supply mix increases.
Negative Factors
Persistent Net Losses
Continued net losses through 2025 show the profitability recovery remains incomplete. Losses have eroded equity and limit retained-capital reinvestment, meaning sustainable earnings improvement must arrive to convert revenue growth and OCF gains into lasting profitability and reduce reliance on external funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent Revenue Growth
Steady revenue growth (including +6.2% in 2025) indicates expanding commercial traction in peptide CDMO services. Durable top-line expansion supports scale economics, underpins capacity investments, and raises the probability of sustained margin recovery if commercial supply mix increases.
Read all positive factors
PolyPeptide Group AG (PPGN) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF1.26B
Dividend YieldN/A
Average Volume (3M)34.07K
Price to Earnings (P/E)―
Beta (1Y)1.21
Revenue Growth13.85%
EPS Growth-7.03%
CountryCH
Employees1,362
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.64
Shares Outstanding33,125,000
10 Day Avg. Volume33,840
30 Day Avg. Volume34,067
Financial Highlights & Ratios
PEG Ratio-5.12
Price to Book (P/B)2.72
Price to Sales (P/S)2.36
P/FCF Ratio-30.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF39.67Price Target Upside33.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.66
Revenue Forecast (FY)CHF482.27M
PolyPeptide Group AG Business Overview & Revenue Model
Company Description
PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinica...
How the Company Makes Money
PolyPeptide Group makes money primarily by providing fee-for-service CDMO work for customers developing and commercializing peptide-based therapeutics. Its core revenue stream is the manufacture and sale of peptide APIs and other peptide-based pro...
PolyPeptide Group AG Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
63
Positive
Cash Flow
51
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 391.87M | 338.69M | 320.37M | 280.98M | 282.13M |
| Gross Profit | 64.32M | 39.27M | 4.77M | 51.99M | 99.70M |
| EBITDA | 44.42M | 28.42M | -22.15M | 35.72M | 83.35M |
| Net Income | -21.31M | -19.56M | -51.44M | 7.77M | 47.26M |
Balance Sheet | |||||
| Total Assets | 825.31M | 756.58M | 689.09M | 575.78M | 595.04M |
| Cash, Cash Equivalents and Short-Term Investments | 74.53M | 68.28M | 95.71M | 37.53M | 136.30M |
| Total Debt | 130.46M | 94.12M | 113.66M | 21.22M | 18.00M |
| Total Liabilities | 484.98M | 399.33M | 307.86M | 154.10M | 173.87M |
| Stockholders Equity | 340.33M | 357.24M | 381.23M | 421.68M | 421.17M |
Cash Flow | |||||
| Free Cash Flow | -30.44M | 2.43M | -20.25M | -69.64M | -16.61M |
| Operating Cash Flow | 78.02M | 89.40M | 36.48M | 5.46M | 57.35M |
| Investing Cash Flow | -112.44M | -91.02M | -59.51M | -78.44M | -80.84M |
| Financing Cash Flow | 34.01M | -25.32M | 84.55M | -26.87M | 130.93M |
PolyPeptide Group AG Technical Analysis
Positive
29.80
Price Trends
27.31
Positive
26.88
Positive
25.62
Positive
Market Momentum
2.81
Negative
74.52
Negative
78.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:PPGN, the sentiment is Positive. The current price of 29.8 is below the 20-day moving average (MA) of 29.90, above the 50-day MA of 27.31, and above the 200-day MA of 25.62, indicating a bullish trend. The MACD of 2.81 indicates Negative momentum. The RSI at 74.52 is Negative, neither overbought nor oversold. The STOCH value of 78.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:PPGN.
PolyPeptide Group AG Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | CHF27.52B | 32.85 | 2.64% | 1.02% | 0.80% | 28043.55% | |
63 Neutral | CHF38.46B | 22.71 | ― | 0.09% | 11.15% | 150.71% | |
62 Neutral | CHF5.31B | 30.18 | 9.76% | 1.43% | 14.84% | 23.77% | |
62 Neutral | CHF3.55B | 19.36 | 15.79% | 0.51% | 2.57% | 4.31% | |
56 Neutral | CHF32.66B | 39.77 | ― | 0.75% | -0.65% | -143.04% | |
54 Neutral | CHF1.26B | -43.40 | ― | ― | 13.85% | -7.03% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
CH:PPGN
PolyPeptide Group AG
38.15
18.71
96.24%
CH:LONN
Lonza Group Ltd
479.20
-114.65
-19.31%
CH:BANB
Bachem Holding AG
70.80
20.30
40.20%
CH:SFZN
Siegfried Holding AG
78.70
-20.09
-20.34%
CH:SDZ
Sandoz Group Ltd
62.54
26.18
72.01%
CH:GALD
Galderma Group AG
163.80
64.92
65.65%
PolyPeptide Group AG Corporate Events
PolyPeptide Confirms Strategic Review Amid Takeover Speculation
Apr 14, 2026
PolyPeptide Group AG, a global CDMO for peptide-based active pharmaceutical ingredients, supports customers from pre-clinical to commercial stages across a broad portfolio, particularly in metabolic diseases. The Swiss-listed company operates a ne...
PolyPeptide shareholders back all proposals at 2026 AGM
Apr 8, 2026
Shareholders of PolyPeptide Group AG approved all board proposals at the company’s fifth ordinary Annual General Meeting, with 26,780,855 voting shares represented, or 80.85% of the issued share capital. The strong turnout underscores solid ...
PolyPeptide expands EUR 200 million credit line to back growth and capacity plans
Mar 19, 2026
PolyPeptide Group AG, a global CDMO specializing in peptide-based active pharmaceutical ingredients for pharma and biotech clients, operates six GMP-certified facilities in Europe, the U.S. and India and is listed on the SIX Swiss Exchange. The co...
PolyPeptide Sets 2026 AGM to Confirm Board and Approve 2025 Reports
Mar 17, 2026
PolyPeptide Group AG has published the invitation to its fifth Annual General Meeting, scheduled for 8 April 2026 at the Chollerhalle in Zug, where all six current board members, including Chairman Peter Wilden, will stand for re-election and key ...
PolyPeptide lifts revenue and margins as peptide demand fuels major capacity build-out
Mar 12, 2026
PolyPeptide Group reported 2025 revenue of EUR 389.3 million, up 15.6% year-on-year, with EBITDA almost doubling and margins improving as higher production volumes, better operational performance and a favorable product mix took effect. Despite a ...
PolyPeptide lifts revenue and margins in 2025 as GLP-1 demand powers growth
Jan 19, 2026
PolyPeptide Group AG reported preliminary, unaudited results showing strong top-line expansion in 2025, with revenue rising around 15.6% year-on-year to approximately EUR 389 million, mainly driven by demand in metabolic therapeutics and rapid gro...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.